Arden G B, Sivaprasad S
City University London, London, UK.
Doc Ophthalmol. 2012 Feb;124(1):15-26. doi: 10.1007/s10633-011-9305-y.
Recent successful trials of antibodies to vascular endothelial growth factor (VEGF) in diabetic retinopathy implicate this cytokine as a major cause of diabetic retinopathy (DR) and diabetic macular oedema (DME). The mechanisms which cause VEGF to be over-expressed to cause the vasculopathy are not entirely clear. This review explores the earliest changes to the retina in DR and the factors that predispose or prevent DR, including sleep apnoea, receptor degenerations laser treatment and VEGF polymorphism. The review also presents the evidence that retinal hypoxia, existing in the earliest stages, causes DR. This hypoxia is much increased by dark adaptation, indicating a new and possibly superior therapy.
近期针对血管内皮生长因子(VEGF)抗体治疗糖尿病性视网膜病变的成功试验表明,这种细胞因子是糖尿病性视网膜病变(DR)和糖尿病性黄斑水肿(DME)的主要病因。导致VEGF过度表达从而引发血管病变的机制尚不完全清楚。本综述探讨了DR中视网膜最早出现的变化以及易患或预防DR的因素,包括睡眠呼吸暂停、受体变性、激光治疗和VEGF基因多态性。该综述还提出了证据,表明最早阶段存在的视网膜缺氧会导致DR。暗适应会使这种缺氧情况大大加剧,这提示了一种新的、可能更有效的治疗方法。